nodes	percent_of_prediction	percent_of_DWPC	metapath
Sunitinib—PAK3—Adaptive Immune System—FRS2—nasal cavity cancer	0.00138	0.00138	CbGpPWpGaD
Sunitinib—MAP2K1—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00138	0.00138	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling by EGFR—FRS2—nasal cavity cancer	0.00138	0.00138	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by FGFR—FRS2—nasal cavity cancer	0.00138	0.00138	CbGpPWpGaD
Sunitinib—JAK2—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00138	0.00138	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00137	0.00137	CbGpPWpGaD
Sunitinib—FGFR1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00137	0.00137	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00137	0.00137	CbGpPWpGaD
Sunitinib—NTRK1—Signaling by NGF—FRS2—nasal cavity cancer	0.00137	0.00137	CbGpPWpGaD
Sunitinib—MAP2K2—DAP12 signaling—FRS2—nasal cavity cancer	0.00137	0.00137	CbGpPWpGaD
Sunitinib—FYN—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00137	0.00137	CbGpPWpGaD
Sunitinib—FGFR1—Signaling by PDGF—FRS2—nasal cavity cancer	0.00136	0.00136	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling by PDGF—FRS2—nasal cavity cancer	0.00136	0.00136	CbGpPWpGaD
Sunitinib—KIT—B Cell Activation—FRS2—nasal cavity cancer	0.00136	0.00136	CbGpPWpGaD
Sunitinib—MAP3K7—B Cell Activation—FRS2—nasal cavity cancer	0.00136	0.00136	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00136	0.00136	CbGpPWpGaD
Sunitinib—JAK2—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00136	0.00136	CbGpPWpGaD
Sunitinib—PDGFRB—Downstream signal transduction—FRS2—nasal cavity cancer	0.00135	0.00135	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling by FGFR—FRS2—nasal cavity cancer	0.00135	0.00135	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00134	0.00134	CbGpPWpGaD
Sunitinib—TYK2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00134	0.00134	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00134	0.00134	CbGpPWpGaD
Sunitinib—PDGFRB—DAP12 signaling—FRS2—nasal cavity cancer	0.00133	0.00133	CbGpPWpGaD
Sunitinib—FGFR2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00133	0.00133	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling by NGF—FRS2—nasal cavity cancer	0.00133	0.00133	CbGpPWpGaD
Sunitinib—JAK2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00132	0.00132	CbGpPWpGaD
Sunitinib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00131	0.00131	CbGpPWpGaD
Sunitinib—LATS2—Signaling Pathways—FRS2—nasal cavity cancer	0.00131	0.00131	CbGpPWpGaD
Sunitinib—FYN—Downstream signal transduction—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Sunitinib—KIT—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Sunitinib—JAK2—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Sunitinib—FYN—Signaling by FGFR—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Sunitinib—MAP2K1—Downstream signal transduction—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Sunitinib—FGFR1—B Cell Activation—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Sunitinib—FYN—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by FGFR—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Sunitinib—PDGFRA—B Cell Activation—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Sunitinib—MAP2K2—DAP12 interactions—FRS2—nasal cavity cancer	0.00128	0.00128	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00128	0.00128	CbGpPWpGaD
Sunitinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00128	0.00128	CbGpPWpGaD
Sunitinib—FYN—DAP12 signaling—FRS2—nasal cavity cancer	0.00128	0.00128	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00128	0.00128	CbGpPWpGaD
Sunitinib—MAP2K1—DAP12 signaling—FRS2—nasal cavity cancer	0.00128	0.00128	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by EGFR—FRS2—nasal cavity cancer	0.00127	0.00127	CbGpPWpGaD
Sunitinib—FYN—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00127	0.00127	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00126	0.00126	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by PDGF—FRS2—nasal cavity cancer	0.00126	0.00126	CbGpPWpGaD
Sunitinib—RPS6KA5—Innate Immune System—FRS2—nasal cavity cancer	0.00126	0.00126	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00125	0.00125	CbGpPWpGaD
Sunitinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00125	0.00125	CbGpPWpGaD
Sunitinib—PDGFRB—DAP12 interactions—FRS2—nasal cavity cancer	0.00125	0.00125	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling by EGFR—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Sunitinib—RPS6KA2—Innate Immune System—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Sunitinib—JAK2—Downstream signal transduction—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Sunitinib—FGFR1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Sunitinib—JAK2—Signaling by FGFR—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
Sunitinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
Sunitinib—JAK2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling by PDGF—FRS2—nasal cavity cancer	0.00123	0.00123	CbGpPWpGaD
Sunitinib—JAK2—DAP12 signaling—FRS2—nasal cavity cancer	0.00122	0.00122	CbGpPWpGaD
Sunitinib—FYN—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00121	0.00121	CbGpPWpGaD
Sunitinib—FYN—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00121	0.00121	CbGpPWpGaD
Sunitinib—FYN—DAP12 interactions—FRS2—nasal cavity cancer	0.00121	0.00121	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00121	0.00121	CbGpPWpGaD
Sunitinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0012	0.0012	CbGpPWpGaD
Sunitinib—MAP2K1—DAP12 interactions—FRS2—nasal cavity cancer	0.0012	0.0012	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0012	0.0012	CbGpPWpGaD
Sunitinib—FYN—Signaling by EGFR—FRS2—nasal cavity cancer	0.0012	0.0012	CbGpPWpGaD
Sunitinib—GRK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.0012	0.0012	CbGpPWpGaD
Sunitinib—CSNK1G2—Signaling Pathways—CXCL11—nasal cavity cancer	0.0012	0.0012	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by EGFR—FRS2—nasal cavity cancer	0.00119	0.00119	CbGpPWpGaD
Sunitinib—FYN—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00119	0.00119	CbGpPWpGaD
Sunitinib—FYN—Signaling by PDGF—FRS2—nasal cavity cancer	0.00118	0.00118	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00118	0.00118	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by PDGF—FRS2—nasal cavity cancer	0.00118	0.00118	CbGpPWpGaD
Sunitinib—PDGFRB—B Cell Activation—FRS2—nasal cavity cancer	0.00116	0.00116	CbGpPWpGaD
Sunitinib—JAK2—DAP12 interactions—FRS2—nasal cavity cancer	0.00115	0.00115	CbGpPWpGaD
Sunitinib—JAK2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00115	0.00115	CbGpPWpGaD
Sunitinib—JAK2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00115	0.00115	CbGpPWpGaD
Sunitinib—JAK2—Signaling by EGFR—FRS2—nasal cavity cancer	0.00114	0.00114	CbGpPWpGaD
Sunitinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00114	0.00114	CbGpPWpGaD
Sunitinib—AXL—Signaling Pathways—CXCL11—nasal cavity cancer	0.00113	0.00113	CbGpPWpGaD
Sunitinib—JAK2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00113	0.00113	CbGpPWpGaD
Sunitinib—JAK2—Signaling by PDGF—FRS2—nasal cavity cancer	0.00112	0.00112	CbGpPWpGaD
Sunitinib—FYN—B Cell Activation—FRS2—nasal cavity cancer	0.00112	0.00112	CbGpPWpGaD
Sunitinib—RPS6KA1—Innate Immune System—FRS2—nasal cavity cancer	0.00112	0.00112	CbGpPWpGaD
Sunitinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00111	0.00111	CbGpPWpGaD
Sunitinib—PHKG1—Disease—FRS2—nasal cavity cancer	0.00107	0.00107	CbGpPWpGaD
Sunitinib—FYN—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00107	0.00107	CbGpPWpGaD
Sunitinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00106	0.00106	CbGpPWpGaD
Sunitinib—IRAK1—Signaling by NGF—FRS2—nasal cavity cancer	0.00106	0.00106	CbGpPWpGaD
Sunitinib—STK11—Signaling Pathways—CXCL11—nasal cavity cancer	0.00104	0.00104	CbGpPWpGaD
Sunitinib—TYK2—Signaling by NGF—FRS2—nasal cavity cancer	0.00103	0.00103	CbGpPWpGaD
Sunitinib—TBK1—Innate Immune System—FRS2—nasal cavity cancer	0.00103	0.00103	CbGpPWpGaD
Sunitinib—FGFR2—Signaling by NGF—FRS2—nasal cavity cancer	0.00102	0.00102	CbGpPWpGaD
Sunitinib—JAK2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00102	0.00102	CbGpPWpGaD
Sunitinib—CSNK1G2—Disease—FRS2—nasal cavity cancer	0.00101	0.00101	CbGpPWpGaD
Sunitinib—GRK1—Disease—FRS2—nasal cavity cancer	0.00101	0.00101	CbGpPWpGaD
Sunitinib—KIT—Signaling by NGF—FRS2—nasal cavity cancer	0.001	0.001	CbGpPWpGaD
Sunitinib—INSR—Signaling Pathways—CXCL11—nasal cavity cancer	0.000998	0.000998	CbGpPWpGaD
Sunitinib—STK4—Signaling Pathways—FRS2—nasal cavity cancer	0.000989	0.000989	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.000962	0.000962	CbGpPWpGaD
Sunitinib—FGFR1—Signaling by NGF—FRS2—nasal cavity cancer	0.000951	0.000951	CbGpPWpGaD
Sunitinib—CSNK2A1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000948	0.000948	CbGpPWpGaD
Sunitinib—FLT4—Signaling Pathways—CXCL11—nasal cavity cancer	0.000948	0.000948	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling by NGF—FRS2—nasal cavity cancer	0.000948	0.000948	CbGpPWpGaD
Sunitinib—ROCK1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.000935	0.000935	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00092	0.00092	CbGpPWpGaD
Sunitinib—IRAK4—Innate Immune System—FRS2—nasal cavity cancer	0.000914	0.000914	CbGpPWpGaD
Sunitinib—PHKG2—Disease—FRS2—nasal cavity cancer	0.00091	0.00091	CbGpPWpGaD
Sunitinib—RPS6KA3—Innate Immune System—FRS2—nasal cavity cancer	0.000889	0.000889	CbGpPWpGaD
Sunitinib—ITK—Immune System—FRS2—nasal cavity cancer	0.000879	0.000879	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by NGF—FRS2—nasal cavity cancer	0.000875	0.000875	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling by NGF—FRS2—nasal cavity cancer	0.000854	0.000854	CbGpPWpGaD
Sunitinib—ROCK1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.000849	0.000849	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—CXCL11—nasal cavity cancer	0.000849	0.000849	CbGpPWpGaD
Sunitinib—STK3—Signaling Pathways—FRS2—nasal cavity cancer	0.000841	0.000841	CbGpPWpGaD
Sunitinib—PAK3—Immune System—FRS2—nasal cavity cancer	0.000838	0.000838	CbGpPWpGaD
Sunitinib—FYN—Signaling by NGF—FRS2—nasal cavity cancer	0.000823	0.000823	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by NGF—FRS2—nasal cavity cancer	0.000819	0.000819	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—CXCL11—nasal cavity cancer	0.000802	0.000802	CbGpPWpGaD
Sunitinib—CSNK2A1—Disease—FRS2—nasal cavity cancer	0.000798	0.000798	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—CXCL11—nasal cavity cancer	0.000794	0.000794	CbGpPWpGaD
Sunitinib—FGR—Innate Immune System—FRS2—nasal cavity cancer	0.000792	0.000792	CbGpPWpGaD
Sunitinib—JAK2—Signaling by NGF—FRS2—nasal cavity cancer	0.000783	0.000783	CbGpPWpGaD
Sunitinib—BLK—Adaptive Immune System—FRS2—nasal cavity cancer	0.000764	0.000764	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000756	0.000756	CbGpPWpGaD
Sunitinib—RPS6KA5—Immune System—FRS2—nasal cavity cancer	0.000731	0.000731	CbGpPWpGaD
Sunitinib—RPS6KA2—Immune System—FRS2—nasal cavity cancer	0.000724	0.000724	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000713	0.000713	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000707	0.000707	CbGpPWpGaD
Sunitinib—CSNK1G2—Signaling Pathways—FRS2—nasal cavity cancer	0.000705	0.000705	CbGpPWpGaD
Sunitinib—GRK1—Signaling Pathways—FRS2—nasal cavity cancer	0.000705	0.000705	CbGpPWpGaD
Sunitinib—AXL—Signaling Pathways—FRS2—nasal cavity cancer	0.000668	0.000668	CbGpPWpGaD
Sunitinib—RPS6KA1—Immune System—FRS2—nasal cavity cancer	0.00065	0.00065	CbGpPWpGaD
Sunitinib—YES1—Innate Immune System—FRS2—nasal cavity cancer	0.00064	0.00064	CbGpPWpGaD
Sunitinib—TYK2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.000637	0.000637	CbGpPWpGaD
Sunitinib—CSNK1A1—Disease—FRS2—nasal cavity cancer	0.000637	0.000637	CbGpPWpGaD
Sunitinib—YES1—Adaptive Immune System—FRS2—nasal cavity cancer	0.000614	0.000614	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—CXCL11—nasal cavity cancer	0.000611	0.000611	CbGpPWpGaD
Sunitinib—STK11—Signaling Pathways—FRS2—nasal cavity cancer	0.000611	0.000611	CbGpPWpGaD
Sunitinib—IRAK1—Innate Immune System—FRS2—nasal cavity cancer	0.000607	0.000607	CbGpPWpGaD
Sunitinib—TBK1—Immune System—FRS2—nasal cavity cancer	0.000597	0.000597	CbGpPWpGaD
Sunitinib—TYK2—Innate Immune System—FRS2—nasal cavity cancer	0.000589	0.000589	CbGpPWpGaD
Sunitinib—INSR—Signaling Pathways—FRS2—nasal cavity cancer	0.000588	0.000588	CbGpPWpGaD
Sunitinib—CAMK2G—Immune System—FRS2—nasal cavity cancer	0.000586	0.000586	CbGpPWpGaD
Sunitinib—FGFR2—Innate Immune System—FRS2—nasal cavity cancer	0.000582	0.000582	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000573	0.000573	CbGpPWpGaD
Sunitinib—MAP3K3—Immune System—FRS2—nasal cavity cancer	0.000573	0.000573	CbGpPWpGaD
Sunitinib—KIT—Innate Immune System—FRS2—nasal cavity cancer	0.000571	0.000571	CbGpPWpGaD
Sunitinib—MAP3K7—Innate Immune System—FRS2—nasal cavity cancer	0.000571	0.000571	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—CXCL11—nasal cavity cancer	0.000568	0.000568	CbGpPWpGaD
Sunitinib—CSNK2A1—Signaling Pathways—FRS2—nasal cavity cancer	0.000559	0.000559	CbGpPWpGaD
Sunitinib—FLT4—Signaling Pathways—FRS2—nasal cavity cancer	0.000559	0.000559	CbGpPWpGaD
Sunitinib—FGFR2—Adaptive Immune System—FRS2—nasal cavity cancer	0.000559	0.000559	CbGpPWpGaD
Sunitinib—MAP3K7—Adaptive Immune System—FRS2—nasal cavity cancer	0.000549	0.000549	CbGpPWpGaD
Sunitinib—KIT—Adaptive Immune System—FRS2—nasal cavity cancer	0.000549	0.000549	CbGpPWpGaD
Sunitinib—FGFR1—Innate Immune System—FRS2—nasal cavity cancer	0.000542	0.000542	CbGpPWpGaD
Sunitinib—PAK3—Signaling Pathways—FRS2—nasal cavity cancer	0.000542	0.000542	CbGpPWpGaD
Sunitinib—PDGFRA—Innate Immune System—FRS2—nasal cavity cancer	0.000541	0.000541	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00054	0.00054	CbGpPWpGaD
Sunitinib—IRAK4—Immune System—FRS2—nasal cavity cancer	0.000532	0.000532	CbGpPWpGaD
Sunitinib—JAK2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.000532	0.000532	CbGpPWpGaD
Sunitinib—FGFR1—Adaptive Immune System—FRS2—nasal cavity cancer	0.000521	0.000521	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.000521	0.000521	CbGpPWpGaD
Sunitinib—PDGFRA—Adaptive Immune System—FRS2—nasal cavity cancer	0.000519	0.000519	CbGpPWpGaD
Sunitinib—RPS6KA3—Immune System—FRS2—nasal cavity cancer	0.000518	0.000518	CbGpPWpGaD
Sunitinib—CSNK1E—Disease—FRS2—nasal cavity cancer	0.000514	0.000514	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.000505	0.000505	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000501	0.000501	CbGpPWpGaD
Sunitinib—PRKAA2—Signaling Pathways—FRS2—nasal cavity cancer	0.0005	0.0005	CbGpPWpGaD
Sunitinib—MAP2K2—Innate Immune System—FRS2—nasal cavity cancer	0.000499	0.000499	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000498	0.000498	CbGpPWpGaD
Sunitinib—PDGFRB—Innate Immune System—FRS2—nasal cavity cancer	0.000487	0.000487	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000483	0.000483	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—CXCL11—nasal cavity cancer	0.000483	0.000483	CbGpPWpGaD
Sunitinib—JAK2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.000483	0.000483	CbGpPWpGaD
Sunitinib—PTK2B—Immune System—FRS2—nasal cavity cancer	0.000474	0.000474	CbGpPWpGaD
Sunitinib—RPS6KA5—Signaling Pathways—FRS2—nasal cavity cancer	0.000473	0.000473	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—CXCL11—nasal cavity cancer	0.000471	0.000471	CbGpPWpGaD
Sunitinib—FYN—Innate Immune System—FRS2—nasal cavity cancer	0.00047	0.00047	CbGpPWpGaD
Sunitinib—RPS6KA2—Signaling Pathways—FRS2—nasal cavity cancer	0.000468	0.000468	CbGpPWpGaD
Sunitinib—PDGFRB—Adaptive Immune System—FRS2—nasal cavity cancer	0.000468	0.000468	CbGpPWpGaD
Sunitinib—MAP2K1—Innate Immune System—FRS2—nasal cavity cancer	0.000467	0.000467	CbGpPWpGaD
Sunitinib—BLK—Immune System—FRS2—nasal cavity cancer	0.000463	0.000463	CbGpPWpGaD
Sunitinib—FGR—Immune System—FRS2—nasal cavity cancer	0.000462	0.000462	CbGpPWpGaD
Sunitinib—FYN—Adaptive Immune System—FRS2—nasal cavity cancer	0.000451	0.000451	CbGpPWpGaD
Sunitinib—JAK2—Innate Immune System—FRS2—nasal cavity cancer	0.000446	0.000446	CbGpPWpGaD
Sunitinib—CSNK1A1—Signaling Pathways—FRS2—nasal cavity cancer	0.000446	0.000446	CbGpPWpGaD
Sunitinib—RPS6KA1—Signaling Pathways—FRS2—nasal cavity cancer	0.00042	0.00042	CbGpPWpGaD
Sunitinib—FLT1—Signaling Pathways—FRS2—nasal cavity cancer	0.000417	0.000417	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000409	0.000409	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000388	0.000388	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—CXCL11—nasal cavity cancer	0.000376	0.000376	CbGpPWpGaD
Sunitinib—YES1—Immune System—FRS2—nasal cavity cancer	0.000373	0.000373	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—CXCL11—nasal cavity cancer	0.000372	0.000372	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—CXCL11—nasal cavity cancer	0.000365	0.000365	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—CXCL11—nasal cavity cancer	0.000365	0.000365	CbGpPWpGaD
Sunitinib—CSNK1E—Signaling Pathways—FRS2—nasal cavity cancer	0.00036	0.00036	CbGpPWpGaD
Sunitinib—IRAK1—Immune System—FRS2—nasal cavity cancer	0.000353	0.000353	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000346	0.000346	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—CXCL11—nasal cavity cancer	0.000346	0.000346	CbGpPWpGaD
Sunitinib—TYK2—Immune System—FRS2—nasal cavity cancer	0.000343	0.000343	CbGpPWpGaD
Sunitinib—FGFR2—Immune System—FRS2—nasal cavity cancer	0.000339	0.000339	CbGpPWpGaD
Sunitinib—PRKAA1—Signaling Pathways—FRS2—nasal cavity cancer	0.000338	0.000338	CbGpPWpGaD
Sunitinib—RPS6KA3—Signaling Pathways—FRS2—nasal cavity cancer	0.000335	0.000335	CbGpPWpGaD
Sunitinib—MAP3K7—Immune System—FRS2—nasal cavity cancer	0.000333	0.000333	CbGpPWpGaD
Sunitinib—KIT—Immune System—FRS2—nasal cavity cancer	0.000333	0.000333	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—CXCL11—nasal cavity cancer	0.000319	0.000319	CbGpPWpGaD
Sunitinib—TYK2—Disease—FRS2—nasal cavity cancer	0.000317	0.000317	CbGpPWpGaD
Sunitinib—FGFR1—Immune System—FRS2—nasal cavity cancer	0.000316	0.000316	CbGpPWpGaD
Sunitinib—PDGFRA—Immune System—FRS2—nasal cavity cancer	0.000315	0.000315	CbGpPWpGaD
Sunitinib—FGFR2—Disease—FRS2—nasal cavity cancer	0.000313	0.000313	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—CXCL11—nasal cavity cancer	0.000311	0.000311	CbGpPWpGaD
Sunitinib—KIT—Disease—FRS2—nasal cavity cancer	0.000307	0.000307	CbGpPWpGaD
Sunitinib—PTK2B—Signaling Pathways—FRS2—nasal cavity cancer	0.000307	0.000307	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—CXCL11—nasal cavity cancer	0.0003	0.0003	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000298	0.000298	CbGpPWpGaD
Sunitinib—ROCK1—Signaling Pathways—FRS2—nasal cavity cancer	0.000295	0.000295	CbGpPWpGaD
Sunitinib—NTRK1—Signaling Pathways—FRS2—nasal cavity cancer	0.000294	0.000294	CbGpPWpGaD
Sunitinib—FGFR1—Disease—FRS2—nasal cavity cancer	0.000292	0.000292	CbGpPWpGaD
Sunitinib—PDGFRA—Disease—FRS2—nasal cavity cancer	0.000291	0.000291	CbGpPWpGaD
Sunitinib—MAP2K2—Immune System—FRS2—nasal cavity cancer	0.000291	0.000291	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—CXCL11—nasal cavity cancer	0.000285	0.000285	CbGpPWpGaD
Sunitinib—RPS6KB1—Signaling Pathways—FRS2—nasal cavity cancer	0.000285	0.000285	CbGpPWpGaD
Sunitinib—MAP2K5—Signaling Pathways—FRS2—nasal cavity cancer	0.000285	0.000285	CbGpPWpGaD
Sunitinib—PDGFRB—Immune System—FRS2—nasal cavity cancer	0.000284	0.000284	CbGpPWpGaD
Sunitinib—KDR—Signaling Pathways—FRS2—nasal cavity cancer	0.000277	0.000277	CbGpPWpGaD
Sunitinib—FYN—Immune System—FRS2—nasal cavity cancer	0.000274	0.000274	CbGpPWpGaD
Sunitinib—MAP2K1—Immune System—FRS2—nasal cavity cancer	0.000272	0.000272	CbGpPWpGaD
Sunitinib—MAP2K2—Disease—FRS2—nasal cavity cancer	0.000268	0.000268	CbGpPWpGaD
Sunitinib—PDGFRB—Disease—FRS2—nasal cavity cancer	0.000262	0.000262	CbGpPWpGaD
Sunitinib—JAK2—Immune System—FRS2—nasal cavity cancer	0.00026	0.00026	CbGpPWpGaD
Sunitinib—FYN—Disease—FRS2—nasal cavity cancer	0.000253	0.000253	CbGpPWpGaD
Sunitinib—MAP2K1—Disease—FRS2—nasal cavity cancer	0.000251	0.000251	CbGpPWpGaD
Sunitinib—YES1—Signaling Pathways—FRS2—nasal cavity cancer	0.000241	0.000241	CbGpPWpGaD
Sunitinib—JAK2—Disease—FRS2—nasal cavity cancer	0.00024	0.00024	CbGpPWpGaD
Sunitinib—IRAK1—Signaling Pathways—FRS2—nasal cavity cancer	0.000228	0.000228	CbGpPWpGaD
Sunitinib—TYK2—Signaling Pathways—FRS2—nasal cavity cancer	0.000222	0.000222	CbGpPWpGaD
Sunitinib—FGFR2—Signaling Pathways—FRS2—nasal cavity cancer	0.000219	0.000219	CbGpPWpGaD
Sunitinib—MAP3K7—Signaling Pathways—FRS2—nasal cavity cancer	0.000215	0.000215	CbGpPWpGaD
Sunitinib—KIT—Signaling Pathways—FRS2—nasal cavity cancer	0.000215	0.000215	CbGpPWpGaD
Sunitinib—FGFR1—Signaling Pathways—FRS2—nasal cavity cancer	0.000204	0.000204	CbGpPWpGaD
Sunitinib—PDGFRA—Signaling Pathways—FRS2—nasal cavity cancer	0.000204	0.000204	CbGpPWpGaD
Sunitinib—MAP2K2—Signaling Pathways—FRS2—nasal cavity cancer	0.000188	0.000188	CbGpPWpGaD
Sunitinib—PDGFRB—Signaling Pathways—FRS2—nasal cavity cancer	0.000183	0.000183	CbGpPWpGaD
Sunitinib—FYN—Signaling Pathways—FRS2—nasal cavity cancer	0.000177	0.000177	CbGpPWpGaD
Sunitinib—MAP2K1—Signaling Pathways—FRS2—nasal cavity cancer	0.000176	0.000176	CbGpPWpGaD
Sunitinib—JAK2—Signaling Pathways—FRS2—nasal cavity cancer	0.000168	0.000168	CbGpPWpGaD
